Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women (BAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01989949
Recruitment Status : Completed
First Posted : November 21, 2013
Last Update Posted : December 17, 2021
Sponsor:
Collaborator:
Department of Health and Human Services
Information provided by (Responsible Party):
La Jolla Pharmaceutical Company ( Tetraphase Pharmaceuticals, Inc. )

Brief Summary:
This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434.

Condition or disease Intervention/treatment Phase
Normal Drug Tolerance Drug: TP-434 (Eravacycline) reconstituted and administered via an IV infusion Phase 1

Detailed Description:

This is a phase 1, open-label, randomized pharmacokinetic and safety study in healthy adult subjects, who will undergo bronchoscopy and bronchoalveolar lavage (BAL) after receiving seven (7) doses of 1.0 mg/kg IV TP-434. Dosing will be twice daily (q12h) for three consecutive days beginning on day one (1) and a morning dose on day four (4).

Approximately 20 subjects will be enrolled into the study at one (1) investigational site. The population for this study is healthy male and female subjects 18 to 65 years of age.

This study includes a Screening Period of up to 30 days, a 4 day, open-label Treatment Period, and a two week Follow-up Period. There will be one 6 day/5 night inpatient stay (Days -1 to 5) during the Treatment Period and one outpatient visit at the end of the Follow-up Period. Excluding the Screening Period, the total duration of confinement (in the Clinical Research Center) will be approximately six (6) days and the total study duration, not including screening, will be approximately three (3) weeks.

Participants will be admitted to the Clinical Research Center on Day -1. Participants will receive four (4) days of intravenous TP-434 1.0 mg/kg of body weight twice daily (q12h) for three consecutive days and a morning dose on day four (4) (for a total of 7 doses) starting on Day 1. Blood and urine samples, ECGs, and vital signs will be collected for safety analysis at specified time points.

Pharmacokinetic blood sampling will occur on Day 4before and after the Day 4 dose of TP-434 at specified time points.

Participants will be randomized to a single BAL procedure time point. Bronchoscopy and BAL will be performed at the following time points after dosing of TP-434 on Day 4: two (2), four (4), six (6), and 12 hours after start of infusion. Bronchoscopy and BAL will be conducted for up to five (5) different participants at each time point. Each subject will undergo bronchoscopy and BAL only once.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Phase 1, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous TP-434 in Healthy Men and Women
Study Start Date : November 2012
Actual Primary Completion Date : January 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TP-434 (Eravacycline) via IV infusion
TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
Drug: TP-434 (Eravacycline) reconstituted and administered via an IV infusion



Primary Outcome Measures :
  1. To determine the steady-state plasma pharmacokinetics and disposition of TP-434 into the epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy adult subjects after intravenous (IV) administration. [ Time Frame: End of Therapy (Day 4) ]

Secondary Outcome Measures :
  1. To determine the safety and tolerability of TP-434 in healthy adult subjects based primarily on the incidence, intensity and type of adverse events (AEs), clinical laboratory assessments, physical examinations, vital signs, and 12-lead ECGs. [ Time Frame: Screening Visit through Day 20 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy males or non-pregnant, non-lactating healthy females
  2. Age >18 to ≤ 65 years of age, inclusive
  3. Body mass index of 18 to 33 kg/m2 or, if outside the range, considered not clinically significant by the Investigator
  4. Must be willing and able to communicate and participate in the whole study
  5. Must provide written informed consent
  6. Must agree to use adequate methods of contraception

Exclusion Criteria:

  1. Participation in a clinical research study within the previous 3 months
  2. Subjects who have previously received TP-434
  3. History of any drug or alcohol abuse in the past 2 years
  4. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  5. Current smokers and those who have smoked within the last 6 months.
  6. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at screening
  7. Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis as judged by the Investigator
  8. Positive tests for drugs of abuse
  9. Positive hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV; I and II) results
  10. History of chronic respiratory disorders as judged by the Investigator
  11. Serious adverse reaction or serious hypersensitivity to tetracyclines, midazolam or like compound, lidocaine or like compounds, or the formulation excipients
  12. Donation or loss of greater than 400 mL of blood within the previous 3 months
  13. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (with the exception of anti inflammatory, anti-hypertensive medications, or hormone replacement therapy) in the 14 days before Investigational Medicinal Product administration unless judged to not interfere with the study objectives according to the Investigator and sponsor's medical monitor
  14. Failure to satisfy the Investigator of fitness to participate for any other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01989949


Locations
Layout table for location information
United States, Connecticut
Center for Anti-infective Research and Development; Hartford Hospital
Hartford, Connecticut, United States, 06102
Sponsors and Collaborators
Tetraphase Pharmaceuticals, Inc.
Department of Health and Human Services
Investigators
Layout table for investigator information
Study Director: Patrick T Horn, MD, PhD Tetraphase Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Tetraphase Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01989949    
Other Study ID Numbers: TP-434-006
First Posted: November 21, 2013    Key Record Dates
Last Update Posted: December 17, 2021
Last Verified: December 2021